Riskpilot← Back to searchSign inGet full accessNahid Farmaci Hägersten AB
ABActiveOrg 5568787138Väpnarevägen 18Retail sale of pharmaceutical products · NACE 4773Est. 20112 employees
Revenue 2024
SEK 16,8M
0% vs 2023
EBITDA margin
3.9%
+8% vs 2023
Equity ratio
61.7%
Financial strength
Net profit 2024
SEK 508K
+6% vs 2023
| Revenue | SEK 16,8M | +0% |
| EBITDA | SEK 655K | +8% |
| Net profit | SEK 508K | +6% |
| Total assets | SEK 5M | +15% |
| Equity | SEK 3,1M | +15% |
| Employees | 2 | — |
Legal name
Nahid Farmaci Hägersten AB
Org number
5568787138
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
27 december 2011
Share capital
SEK 100 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget har till föremål för sin verksamhet att bedriva handel med receptbelagda apoteksvaror, receptfria apoteksvaror och handelsvaror som lämpar sig för försäljning och distribution till konsumenter genom apotek samt därmed förenlig verksamhet.
Address
Väpnarevägen 18
Phone
+46771450450
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 11 290 | 13 758 | 15 668 | 16 831 | 16 840 |
| Staff expenses | — | — | −923 | −977 | −1 056 |
| EBITDA | 704 | 746 | 464 | 608 | 655 |
| Depreciation & amort. | −253 | −86 | −3 | — | — |
| EBIT | 451 | 660 | 461 | 608 | 655 |
| Net financials | −12 | — | 0 | 1 | −7 |
| Profit before tax | 438 | 660 | — | — | — |
| Tax | −0 | −54 | −101 | −132 | −140 |
| Net profit | 438 | 606 | 360 | 478 | 508 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 207 | 3 741 | 4 181 | 4 362 | 5 022 |
| Equity | 1 348 | 1 954 | 2 314 | 2 692 | 3 100 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 1 859 | 1 787 | 1 867 | 1 670 | 1 923 |
| Total debt | 1 859 | 1 787 | 1 867 | 1 670 | 1 923 |
EBITDA margin
3.9%
This company
15.8%
Market median
-75% vs market
20202024
Equity ratio
61.7%
This company
38.2%
Market median
+62% vs market
20202024
Return on equity
16.4%
This company
18.4%
Market median
+11% vs market
20202024
Net profit margin
3.0%
This company
8.1%
Market median
-63% vs market
20202024
Asset turnover
3.35×
This company
1.12×
Market median
+199% vs market
20202024
Debt / equity
0.62×
This company
0.62×
Market median
+0% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
ME Chief Auditor | Chief Auditor | 2025 |
NM Chief Executive Officer | Chief Executive Officer | 2020 |
| Former (2) | ||
LM Chief Auditor | Chief Auditor | 2020 – 2022 |
JL Chief Auditor | Chief Auditor | 2022 – 2025 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Nahid Farmaci Hägersten AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Malin Elisabeth Terneblad | Chief Auditor | 0 companies |
| Lars Michael Magnusson | Chief Auditor | 0 companies |
| Nahid Månsson | Chief Executive Officer | 0 companies |
| Jonas Lars Lindgren | Chief Auditor | 0 companies |
| Edward Christian Johansson | Deputy Board Member | 0 companies |